{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:39:46Z","timestamp":1769693986709,"version":"3.49.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":145,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Commonly, acquired pure red cell aplasia (PRCA) can be associated with an underlying autoimmune disease. Reports of PRCA associated with systemic lupus erythematosus (SLE) are rare, and no treatment strategies have been documented. We report a case of PRCA associated with SLE that responded to intravenous cyclophosphamide (IVCY) and systemic corticosteroids. A 62-year-old Japanese female was diagnosed with PRCA and SLE. At the time of the initial visit, the patient simultaneously presented with severe proteinuria, massive pleural effusion, and interstitial changes. Notably, cyclosporine and corticosteroids did not improve PRCA and SLE status of the patient. After IVCY and corticosteroid administration, the patient\u2019s reticulocyte count and anaemia improved. Various other symptoms associated with SLE also improved. Cyclophosphamide is typically administered in PRCA in small, continuous oral doses. However, in this case, we did not need to initiate this continuous, low-dose treatment after IVCY. Overall, this study highlights therapeutic strategies involving IVCY in treating PRCA associated with SLE.<\/jats:p>","DOI":"10.1093\/mrcr\/rxaf024","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T09:36:07Z","timestamp":1747992967000},"source":"Crossref","is-referenced-by-count":1,"title":["Successful treatment by systemic corticosteroids and intravenous cyclophosphamide in acquired pure red cell aplasia associated with systemic lupus erythematosus"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4776-4249","authenticated-orcid":false,"given":"Takafumi","family":"Tsushima","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Narita Hospital , Narita, Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Fukuta","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Japanese Red Cross Narita Hospital , Narita, Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsumi","family":"Yoda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Narita Hospital , Narita, Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiharu","family":"Kimeda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Narita Hospital , Narita, Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazusuke","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Narita Hospital , Narita, Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Narita Hospital , Narita, Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Hatanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Narita Hospital , Narita, Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rena","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Narita Hospital , Narita, Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonoko","family":"Shimoji","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Narita Hospital , Narita, Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Utsu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Narita Hospital , Narita, Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Ichi","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Narita Hospital , Narita, Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Aotsuka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Narita Hospital , Narita, Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"2025080201024988800_ref1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2141.2008.07216.x","article-title":"Acquired pure red cell aplasia: updated review of treatment","volume":"142","author":"Sawada","year":"2008","journal-title":"Br J Haematol"},{"key":"2025080201024988800_ref2","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1182\/blood.2021010898","article-title":"How I manage acquired pure red cell aplasia in adults","volume":"137","author":"Gurnari","year":"2021","journal-title":"Blood"},{"key":"2025080201024988800_ref3","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1182\/blood-2016-05-717140","article-title":"Pure red cell aplasia","volume":"128","author":"Means","year":"2016","journal-title":"Blood"},{"key":"2025080201024988800_ref4","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2025080201024988800_ref5","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"2025080201024988800_ref6","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025080201024988800_ref7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/rheumatology\/keab363","article-title":"Pure red cell aplasia in systemic lupus erythematosus, a nationwide retrospective cohort and review of the literature","volume":"61","author":"Lobbes","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025080201024988800_ref8","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00296-023-05306-5","article-title":"Current treatment of systemic lupus erythematosus: a clinician\u2019s perspective","volume":"43","author":"Katarzyna","year":"2023","journal-title":"Rheumatol Int"},{"key":"2025080201024988800_ref9","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025080201024988800_ref10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2025080201024988800_ref11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/14397595.2019.1709944","article-title":"2019 Diagnostic criteria for mixed connective tissue disease (MCTD): from the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2025080201024988800_ref12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/blood.V59.1.114.114","article-title":"Mode of action of the IgG inhibitor of erythropoiesis in transient erythroblastopenia of children","volume":"59","author":"Dessypris","year":"1982","journal-title":"Blood"},{"key":"2025080201024988800_ref13","first-page":"275","article-title":"The biology of pure red cell aplasia","volume":"28","author":"Dessypris","year":"1991","journal-title":"Semin Hematol"},{"key":"2025080201024988800_ref14","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1182\/blood.V87.7.3000.bloodjournal8773000","article-title":"Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities","volume":"87","author":"Lacy","year":"1996","journal-title":"Blood"},{"key":"2025080201024988800_ref15","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/j.1365-2141.2000.02429.x","article-title":"Pure red cell aplasia","volume":"111","author":"Fisch","year":"2000","journal-title":"Br J Haematol"},{"key":"2025080201024988800_ref16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0049-0172(92)90009-3","article-title":"Mechanisms of action of cyclosporine and effects on connective tissues","volume":"21","author":"Russell","year":"1992","journal-title":"Semin Arthritis Rheum"},{"key":"2025080201024988800_ref17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/art.1780180113","article-title":"The effect of cyclophosphamide on B and T lymphocytes in patients with connective tissue diseases","volume":"18","author":"Hurd","year":"1975","journal-title":"Arthritis Rheum"},{"key":"2025080201024988800_ref18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.1365-2249.2002.01777.x","article-title":"Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs","volume":"128","author":"Strauss","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"2025080201024988800_ref19","first-page":"759","article-title":"Successful treatment of pure red cell aplasia in systemic lupus erythematosus with cyclosporin A","volume":"21","author":"Atzeni","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"2025080201024988800_ref20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12288-008-0008-9","article-title":"Cyclosporine A responsive pure red cell aplasia in a child with systemic lupus erythematosus","volume":"23","author":"Biswal","year":"2007","journal-title":"Indian J Hematol Blood Transfus"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxaf024\/63354937\/rxaf024.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf024\/63354937\/rxaf024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf024\/63354937\/rxaf024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T05:02:53Z","timestamp":1754110973000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxaf024\/8149112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxaf024","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"rxaf024"}}